CHR1 | GENE1 | SNP1 | CHR2 | GENE2 | SNP2 | The odds ratio for interaction | Chi-square | P-value | FDR-adjusted P-value |
---|---|---|---|---|---|---|---|---|---|
Patients with dyslipidemia by K/DOQI vs. patients without this phenotype | |||||||||
9 | ENHO | rs2281997 | 9 | RXRA | RXRA | 1.7690 | 7.007 | 0.0081 | 0.3645 |
Patients with LDL-cholesterol ≥100 mg/dL vs. patients without this phenotype | |||||||||
3 | CASR | rs1801725 | 9 | RXRA | rs10881578 | 0.6030 | 4.048 | 0.0442 | 0.9916 |
9 | ENHO | rs2281997 | 9 | RXRA | rs749759 | 1.8920 | 8.794 | 0.0030 | 0.1350 |
Patients with non-HDL-cholesterol ≥130 mg/dL and TG ≥ 200 mg/dL vs patients without this phenotype | |||||||||
9 | ENHO | rs2281997 | 11 | LXRA | rs2279238 | 2.4220 | 5.962 | 0.0146 | 0.3285 |
9 | RXRA | rs10881578 | 9 | RXRA | rs749759 | 0.4213 | 9.829 | 0.0017 | 0.0765 |
Patients with atherogenic index ≥3.8 vs. patients without this phenotype | |||||||||
3 | CASR | rs7652589 | 9 | ENHO | rs72735260 | 0.5744 | 4.680 | 0.0305 | 0.8595 |
9 | ENHO | rs2281997 | 11 | LXRA | rs2279238 | 1.7750 | 4.298 | 0.0382 | 0.8595 |
Patients with dyslipidemia by K/DOQI vs. patients without dyslipidemia by all used criteria | |||||||||
9 | ENHO | rs2281997 | 9 | RXRA | rs749759 | 1.767 | 5.528 | 0.0187 | 0.8415 |
Patients with LDL-cholesterol ≥100 mg/dL vs. patients without dyslipidemia by all used criteria | |||||||||
9 | ENHO | rs2281997 | 9 | RXRA | rs749759 | 1.945 | 6.839 | 0.0089 | 0.4005 |
Patients with non-HDL-cholesterol ≥130 mg/dL and TG ≥ 200 mg/dL vs. patients without dyslipidemia by all used criteria | |||||||||
9 | ENHO | rs2281997 | 11 | LXRA | rs2279238 | 2.604 | 5.017 | 0.0251 | 0.5648 |
9 | RXRA | rs10881578 | 9 | RXRA | rs749759 | 0.485 | 5.743 | 0.0166 | 0.5648 |
Patients with atherogenic index ≥3.8 vs. patients without dyslipidemia by all used criteria | |||||||||
3 | CASR | rs7652589 | 9 | ENHO | rs72735260 | 0.564 | 3.904 | 0.0482 | 0.8162 |